Feasibility of interstitial stepping-source electronic brachytherapy to locally inoperable tumors.
Intrabeam
electronic brachytherapy
interstitial brachytherapy
iodine seeds
stepping source
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
24
02
2020
accepted:
16
07
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
11
12
2020
Statut:
ppublish
Résumé
Radiotherapy is the mainstay in the treatment of locally inoperable tumors. Interstitial electronic needle-based kilovoltage brachytherapy (EBT) could be an economic alternative to high-dose-rate (HDR) brachytherapy or permanent seed implantation (PSI). In this work, we evaluated if locally inoperable tumors treated with PSI at our institution may be suitable for EBT. A total of 10 post-interventional computed tomography (CT) scans of patients, who received PSI and simulated stepping-source EBT applied with Intrabeam system and needle applicator were used. EBT treatment planning software with 3-dimensional image and projection of applicator were applied for designing trajectories and establishing dwell positions. Dwell position doses were summarized, and doses covering 90% of the target volume (D In all patients, D Stepping-source EBT allowed for a conformal treatment of inoperable interstitial tumors with similar D
Identifiants
pubmed: 33299437
doi: 10.5114/jcb.2020.100381
pii: 42249
pmc: PMC7701928
doi:
Types de publication
Journal Article
Langues
eng
Pagination
480-486Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
AMR, LI, JH, UO, and FW have nothing to disclose. FS, YAM, and FB report personal fees from CARL ZEISS MEDITEC AG, outside the submitted work. GRS reports grants and personal fees from CARL ZEISS MEDITEC AG, outside the submitted work. FG reports personal fees from Siemens Healthcare Diagnostics GmbH, grants, and personal fees from NOXXON Pharma AG, grants and personal fees from CARL ZEISS MEDITEC AG, personal fees from Merck Serono GmbH, personal fees from Roche Pharma AG, outside the submitted work; in addition, FG has a patent (US 62/435405) pending.
Références
J Neurosurg Sci. 2018 Apr;62(2):214-220
pubmed: 26771176
Med Phys. 2012 Oct;39(10):6208-36
pubmed: 23039658
Radiother Oncol. 2010 Dec;97(3):514-20
pubmed: 20950878
Radiother Oncol. 1983 Nov;1(2):187-91
pubmed: 6680223
Z Med Phys. 2014 Sep;24(3):243-51
pubmed: 24238628
Minim Invasive Ther Allied Technol. 2010 Aug;19(4):189-202
pubmed: 20642386
Z Med Phys. 2012 Sep;22(3):197-204
pubmed: 22739321
Pathol Oncol Res. 2019 Jan;25(1):327-332
pubmed: 29116622
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1127-33
pubmed: 22981707
J Contemp Brachytherapy. 2010 Dec;2(4):163-170
pubmed: 27853479
Strahlenther Onkol. 2003 Jul;179(7):458-63
pubmed: 12835882
Front Oncol. 2018 Mar 26;8:74
pubmed: 29632850
Pract Radiat Oncol. 2015 May-Jun;5(3):e201-e206
pubmed: 25413406
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1298-305
pubmed: 19545794
Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):515-24
pubmed: 9457842
Head Neck. 2018 Jul;40(7):1524-1533
pubmed: 29573121
Br J Radiol. 2015 Aug;88(1052):20150010
pubmed: 25996576
Br J Radiol. 2011 Nov;84(1007):1034-9
pubmed: 21304003
J Appl Clin Med Phys. 2019 Jul;20(7):78-86
pubmed: 31183970
Br J Radiol. 2015 May;88(1049):20150002
pubmed: 25748070
Neurosurgery. 2019 Jan 1;84(1):41-49
pubmed: 29528443
Lancet. 2014 Feb 15;383(9917):603-13
pubmed: 24224997
Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):731-6
pubmed: 9112473
J Cancer Res Ther. 2016 Dec;12(Supplement):C176-C180
pubmed: 28230013
Med Phys. 2008 Dec;35(12):5385-96
pubmed: 19175098
Brachytherapy. 2013 Mar-Apr;12(2):134-40
pubmed: 23312675
BMC Cancer. 2019 May 9;19(1):430
pubmed: 31072314
Radiat Oncol. 2018 May 16;13(1):96
pubmed: 29769103
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1392-400
pubmed: 19464825
Radiat Prot Dosimetry. 2015 Apr;164(3):376-82
pubmed: 25267855